A meta-analysis by Zhao et al. reported an increased incidence of hypertension associated with some anti-TNF therapies (OR = 1.8896, 95% CI: 1.35–2.65), as well as an increased incidence of hypertension with longer therapy durations, associated with certolizumab but not with etanercept, tofacitinib, infliximab, and golimumab [126]. Here, TNF is linked to hypertensive disorder.